Hims & Hers: Navigating GLP Controversy With Aplomb, But Risks Warrant Hold Rating

Get the latest analysis on Hims & Hers Health, Inc. stock with valuation insights, business risks, and forecasts. Click here ...

Targeting Hims & Hers, F.D.A. Takes on a New Type of Drug Advertiser

Regulators sent about 100 warning letters this week to drug advertisers, including to Hims & Hers, a major online provider of weight-loss drugs.

U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims

The U.S. Food and Drug Administration issued warning letters to Eli Lilly , Novo Nordisk and telehealth firm Hims & Hers ...
PharmTech

Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications

Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk ...
PharmExec

FDA Sends Warning Letters to Novo Nordisk, Eli Lilly, and Hims Regarding Misleading Pharmaceutical Advertising

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and ...

US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs

The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss ...

Why copycat Ozempic is everywhere

Online pharmacies are using a loophole to continue selling cheap weight loss drugs that are modeled on Ozempic and Mounjaro, ...
Hosted on MSN

Here’s Why Wall Street Is Cautious on Hims & Hers Health Stock (HIMS)

Telehealth and wellness platform Hims & Hers Health (HIMS) recently disappointed investors with its mixed second-quarter results. While the company’s Q2 revenue grew 73% to about $545 million, it ...